A REMS (Risk Evaluation and Mitigation Strategy) is a safety program the FDA can require for medications that carry serious risks. It goes beyond the standard warning label: a REMS creates specific rules that doctors, pharmacists, and sometimes patients must follow before a drug can be prescribed, dispensed, or taken. The FDA has approved more than 300 REMS programs since 2008, but only a small fraction of all medications on the market require one.
Most drugs communicate their risks through prescribing information and package inserts. A REMS exists when the FDA determines those standard tools aren’t enough on their own. The program focuses on preventing, monitoring, or managing one specific serious risk, not every possible side effect a drug might cause.
Why Certain Drugs Require a REMS
The FDA requires a REMS when a medication’s benefits are significant enough to keep it available, but its risks are serious enough that extra safeguards are needed. Think of it as a structured compromise: rather than pulling a valuable drug from the market, the FDA builds guardrails around how it’s used. A drug for treatment-resistant schizophrenia, for example, might be the only option for some patients, but it can cause dangerously low white blood cell counts. The REMS program for that drug (clozapine) requires regular blood monitoring before each refill to catch the problem early.
The types of risks that trigger a REMS vary widely. Some drugs can cause severe birth defects if taken during pregnancy. Others carry risks of addiction, life-threatening allergic reactions, or organ damage. In each case, the REMS targets that one specific danger with tailored safety steps.
What a REMS Program Includes
Not every REMS looks the same. The FDA tailors each program to match the specific risk, so some are relatively simple while others involve multiple layers of requirements. There are three main building blocks.
Medication Guides
These are FDA-approved handouts written in patient-friendly language, distributed when the medication is dispensed or administered. They explain how to use the drug safely and what serious side effects to watch for. This is the lightest form of a REMS, essentially a more detailed and mandatory version of the information sheet you might already get stapled to your pharmacy bag.
Communication Plans
Some REMS programs require the drug manufacturer to reach out directly to healthcare providers, pharmacists, nurses, and even medical professional societies or state licensing boards. These communications highlight the specific serious risk and outline steps to reduce it. The goal is to make sure everyone involved in prescribing and dispensing the drug understands what to watch for.
Elements to Assure Safe Use
This is where REMS programs get more involved. Known as ETASU, these are mandatory actions that must happen before a medication can be prescribed, dispensed, or received. They can include any combination of the following:
- Prescriber certification: Doctors must enroll in the REMS program, complete training, review educational materials, and sometimes pass a knowledge assessment before they’re allowed to write prescriptions for the drug.
- Pharmacy certification: Only pharmacies that have been certified through the REMS program can fill prescriptions for the medication.
- Patient enrollment: Patients sign an enrollment form acknowledging they understand the risks and agree to follow specific safety steps.
- Lab testing or monitoring: Some programs require documented lab results (like a blood test or pregnancy test) before each prescription can be filled.
- Supervised administration: Certain drugs must be taken in a healthcare setting under direct observation, with a monitoring period afterward.
These requirements often work in combination. A single REMS might require certified prescribers, certified pharmacies, patient enrollment forms, and monthly lab work all at once.
What Patients Experience
If your medication has a REMS, you’ll likely notice extra steps at the doctor’s office or pharmacy that don’t apply to your other prescriptions. The specifics depend on the drug, but a typical experience might involve signing an enrollment form with your doctor, acknowledging that you understand the medication’s risks. Your doctor fills out most of the paperwork and submits it to the REMS program on your behalf.
For some medications, you’ll need to complete lab work on a set schedule. Your prescription won’t be filled until those results are documented. For others, you may need to take the medication in a clinic rather than at home, with a healthcare provider watching for a set period afterward. One nasal spray antidepressant, for instance, requires at least two hours of monitoring after each dose, and patients cannot drive until the following day after a full night’s sleep.
These steps can feel burdensome, especially for medications taken long-term. But they exist because the specific risk the REMS targets is serious enough that the FDA determined routine prescribing wasn’t safe enough on its own.
How the FDA Monitors REMS Programs
REMS programs aren’t set-and-forget. Drug manufacturers must submit formal assessments to the FDA at 18 months after the program is approved, again at 3 years, and again in the 7th year. The FDA can increase or decrease the frequency of these check-ins depending on how the program is performing. If a REMS is working well and the data supports it, the FDA can reduce requirements or eliminate the program entirely. If problems emerge, requirements can be tightened.
Since 2008, the FDA has approved over 700 modifications to existing REMS programs, which gives a sense of how actively these programs evolve over time.
How Generic Drugs Fit In
When a generic version of a REMS drug comes to market, federal law generally requires the generic manufacturer to use the same shared system as the brand-name drug rather than creating a separate program. This means patients and prescribers follow one set of rules regardless of which version of the drug they use.
In practice, brand-name and generic manufacturers form working groups to negotiate how to share costs, manage a joint database, and run a single call center. They submit their shared REMS documentation to the FDA through a single filing, which prevents the confusion that would come from having multiple overlapping safety programs for the same medication. The FDA can waive this shared-system requirement in certain cases, but the default is a unified program.
Common Drugs With REMS Programs
You’re most likely to encounter a REMS if you’re prescribed a medication in one of a few categories. Opioid painkillers have some of the most well-known REMS programs, focused on reducing the risks of addiction, misuse, and overdose. Clozapine, used for treatment-resistant schizophrenia, requires regular blood monitoring because it can cause a dangerous drop in white blood cells called severe neutropenia. Isotretinoin, a powerful acne medication, has a REMS centered on preventing pregnancy during treatment because it causes severe birth defects. Certain cancer drugs that are related to thalidomide carry similar pregnancy-prevention requirements.
Some newer medications for conditions like treatment-resistant depression require in-clinic administration and post-dose monitoring, reflecting risks like sedation and dissociation that make it unsafe for patients to take the drug unsupervised.
The full list of active REMS programs is publicly available on the FDA’s REMS Public Dashboard, which is searchable by drug name if you want to check whether a specific medication has one.